TEL AVIV, Israel, Oct. 30, 2019 /PRNewswire/ -- Galmed
Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a
clinical-stage biopharmaceutical company focused on the development
of Aramchol, a liver targeted, oral, SCD1 modulator, currently in
Phase 3/4 clinical trial for the treatment of nonalcoholic
steatohepatitis (NASH) and fibrosis announced today that it
will host a conference call and webcast on Wednesday, November 6, 2019, to provide an update
on current developments with respect to its clinical programs for
Aramchol™ and to discuss financial results for the
three and nine months ended September 30,
2019.
Conference Call & Webcast:
Wednesday, November 6th @
8:30am Eastern Time.
Toll Free: 1-855-327-6837
Toll/International: 1-631-891-4304
Israel Toll Free: 1-809-458-327
Conference ID: 10007881
Webcast: http://public.viavid.com/index.php?id=136591
Replay Dial-In Numbers
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 10007881
Replay Start: Wednesday, November 6,
2019, 11:30 AM ET
Replay Expiry: Wednesday, November 20,
2019, 11:59 PM ET
About Aramchol and Non-alcoholic Steatohepatitis
(NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol's ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol on fibrosis is mediated by downregulation of steatosis and
directly on human collagen producing cells. Aramchol has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development
biopharmaceutical company for liver, metabolic and inflammatory
diseases. Our lead compound, Aramchol™, a backbone
drug candidate for the treatment of NASH and fibrosis is currently
in a Phase 3/4 registrational study.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-wednesday-november-6-300948048.html
SOURCE Galmed Pharmaceuticals Ltd.